Cancer Research and Treatment

Original Articles

Identification of Significant Prognostic Tissue Markers Associated with Survival in Upper Urinary Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy: A Retrospective Immunohistochemical Analysis Using Tissue Microarray: Sung Han Kim, Weon Seo Park, Boram Park, Jinsoo Chung, Jae Young Joung, Kang Hyun Lee, Ho Kyung Seo; Cancer Res Treat. 2020;52(1):128-138. Published online June 19, 2019; DOI: https://doi.org/10.4143/crt.2019.119

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to identify prognostic tissue markers for several survival outcomes after radical nephroureterectomy among patients with upper urinary tract urothelial carcinoma using tissue microarray and immunohistochemistry.
Materials and Methods
Retrospectively, data of 162 non-metastatic patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy between 2004 and 2016 were reviewed to determine intravesical recurrence-free survival (IVRFS), disease-free survival (DFS), and overall survival (OS). The expression of 27 tissue markers on a tissue microarray of radical nephroureterectomy samples and prognostic values of clinicopathological parameters were evaluated using immunohistochemistry and Cox proportional hazard models after adjusting for significant prognostic clinicopathological variables. The expression of all tissue markers was categorized into a binary group with continuous H-scores (0-300).
Results
Median follow-up was 53.4 months (range, 3.6 to 176.5 months); and, 58 (35.8%), 48 (29.6%), and 19 (11.7%) bladder recurrence, disease progression, and all cause death, respectively, were identified. After adjusting for significant clinicopathological factors including intravesical instillation for bladder recurrence-free survival, pathologic T category and intravesical instillation for disease progression-free survival , and pathologic T category for OS (p < 0.05), IVRFS was associated with epithelial cadherin (hazard ratio [HR], 0.49), epidermal growth factor receptor/erythroblastosis oncogene B (c-erb) (HR, 2.59), and retinoblastoma protein loss (HR, 1.85); DFS was associated with cyclin D1 (HR, 2.16) and high-molecular-weight cytokeratin (HR, 0.42); OS was associated with E-cadherin (HR, 0.34) and programmed cell death 1 ligand (HR, 13.42) (p < 0.05).
Conclusion
Several significant tissue markers were associated with survival outcomes in upper urinary tract urothelial carcinoma patients treated with radical nephroureterectomy.

Citations

Citations to this article as recorded by

A multi‐institutional retrospective study of open versus laparoscopic nephroureterectomy focused on the intravesical recurrence
Soichiro Shimura, Kazumasa Matsumoto, Masaomi Ikeda, Shigenori Moroo, Dai Koguchi, Yoshinori Taoka, Takahiro Hirayama, Yasukiyo Murakami, Takuji Utsunomiya, Daisuke Matsuda, Norihiko Okuno, Akira Irie, Masatsugu Iwamura
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 71. CrossRef
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario
Giulia Mazzaschi, Giulia Claire Giudice, Matilde Corianò, Davide Campobasso, Fabiana Perrone, Michele Maffezzoli, Irene Testi, Luca Isella, Umberto Maestroni, Sebastiano Buti
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Prognostic value of programmed death ligand‐1 and programmed death‐1 expression in patients with upper tract urothelial carcinoma
Luca Campedel, Eva Compérat, Géraldine Cancel‐Tassin, Justine Varinot, Christian Pfister, Clara Delcourt, Françoise Gobet, Mathieu Roumiguié, Pierre‐Marie Patard, Gwendoline Daniel, Pierre Bigot, Julie Carrouget, Caroline Eymerit, Stéphane Larré, Priscill
BJU International.2023; 132(5): 581. CrossRef
The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
Yi Lu, Jiaqi Kang, Zhiwen Luo, Yuxuan Song, Jia Tian, Zhongjia Li, Xiao Wang, Li Liu, Yongjiao Yang, Xiaoqiang Liu
Frontiers in Oncology.2020;[Epub] CrossRef

7,361 View
142 Download
4 Web of Science
4 Crossref

Nomogram Development and External Validation for Predicting the Risk of Lymph Node Metastasis in T1 Colorectal Cancer: Jung Ryul Oh, Boram Park, Seongdae Lee, Kyung Su Han, Eui-Gon Youk, Doo-Han Lee, Do-Sun Kim, Doo-Seok Lee, Chang Won Hong, Byung Chang Kim, Bun Kim, Min Jung Kim, Sung Chan Park, Dae Kyung Sohn, Hee Jin Chang, Jae Hwan Oh; Cancer Res Treat. 2019;51(4):1275-1284. Published online January 17, 2019; DOI: https://doi.org/10.4143/crt.2018.569

Abstract PDF Supplementary Material PubReader ePub

Purpose
Predicting lymph node metastasis (LNM) risk is crucial in determining further treatment strategies following endoscopic resection of T1 colorectal cancer (CRC). This study aimed to establish a new prediction model for the risk of LNM in T1 CRC patients.
Materials and Methods
The development set included 833 patients with T1 CRC who had undergone endoscopic (n=154) or surgical (n=679) resection at the National Cancer Center. The validation set included 722 T1 CRC patients who had undergone endoscopic (n=249) or surgical (n=473) resection at Daehang Hospital. A logistic regression model was used to construct the prediction model. To assess the performance of prediction model, discrimination was evaluated using the receiver operating characteristic (ROC) curves with area under the ROC curve (AUC), and calibration was assessed using the Hosmer-Lemeshow (HL) goodness-of-fit test.
Results
Five independent risk factors were determined in the multivariable model, including vascular invasion, high-grade histology, submucosal invasion, budding, and background adenoma. In final prediction model, the performance of the model was good that the AUC was 0.812 (95% confidence interval [CI], 0.770 to 0.855) and the HL chi-squared test statistic was 1.266 (p=0.737). In external validation, the performance was still good that the AUC was 0.771 (95% CI, 0.708 to 0.834) and the p-value of the HL chi-squared test was 0.040. We constructed the nomogram with the final prediction model.
Conclusion
We presented an externally validated new prediction model for LNM risk in T1 CRC patients, guiding decision making in determining whether additional surgery is required after endoscopic resection of T1 CRC.

Citations

Citations to this article as recorded by

Risk stratification scores for lymph node metastases in T1 colorectal cancer—A systematic review
Rakesh Quinn, Giuleta Jamsari, Ewan MacDermid
Colorectal Disease.2025;[Epub] CrossRef
The critical role of tumor size in predicting lymph node metastasis in early-stage colorectal cancer
Attila Ulkucu, Metincan Erkaya, Ekin Inal, Emre Gorgun
The American Journal of Surgery.2025; 241: 116152. CrossRef
Pitfalls during histological assessment in locally resected pT1 colorectal cancer
Emma J Norton, Adrian C Bateman
Histopathology.2025;[Epub] CrossRef
Artificial intelligence-based model to predict recurrence after local excision in T1 rectal cancer
Jiarui Su, Zhiyuan Liu, Haiming Li, Li Kang, Kaihong Huang, Jiawei Wu, Han Huang, Fei Ling, Xueqing Yao, Chengzhi Huang
European Journal of Surgical Oncology.2025; 51(6): 109717. CrossRef
Prediction of lymph node metastasis in stage I–III colon cancer patients younger than 40 years
Wei-Hao Zhang, Meng-Di Huang, Yan-Ling Tu, Kun-Zhai Huang, Chao-Jun Wang, Zhao-Hui Liu, Rui-Sheng Ke
Clinical and Translational Oncology.2025;[Epub] CrossRef
Risk assessment in pT1 colorectal cancer
Emma Jane Norton, Adrian C Bateman
Journal of Clinical Pathology.2024; 77(4): 225. CrossRef
Curative criteria for endoscopic treatment of colorectal cancer
Lucille Quénéhervé, Mathieu Pioche, Jérémie Jacques
Best Practice & Research Clinical Gastroenterology.2024; 68: 101883. CrossRef
Commentary: An artificial intelligence prediction model outperforms conventional guidelines in predicting lymph node metastasis of T1 colorectal cancer
Katsuro Ichimasa, Shin-ei Kudo, Khay Guan Yeoh
Frontiers in Oncology.2024;[Epub] CrossRef
Management after non-curative endoscopic resection of T1 rectal cancer
Hao Dang, Daan A. Verhoeven, Jurjen J. Boonstra, Monique E. van Leerdam
Best Practice & Research Clinical Gastroenterology.2024; 68: 101895. CrossRef
A clinical-radiomics nomogram based on spectral CT multi-parameter images for preoperative prediction of lymph node metastasis in colorectal cancer
Qian Li, Rui Hong, Ping Zhang, Liting Hou, Hailun Bao, Lin Bai, Jian Zhao
Clinical & Experimental Metastasis.2024; 41(5): 639. CrossRef
A new clinical model for predicting lymph node metastasis in T1 colorectal cancer
Kai Wang, Hui He, Yanyun Lin, Yanhong Zhang, Junguo Chen, Jiancong Hu, Xiaosheng He
International Journal of Colorectal Disease.2024;[Epub] CrossRef
Predictors of early colorectal cancer metastasis to lymph nodes: providing rationale for therapy decisions
Xu Song, Jun Li, Jiang Zhu, Yun-Fei Kong, Yu-Hang Zhou, Zi-Kun Wang, Jin Zhang
Frontiers in Oncology.2024;[Epub] CrossRef
Approaches and considerations in the endoscopic treatment of T1 colorectal cancer
Yunho Jung
The Korean Journal of Internal Medicine.2024; 39(4): 563. CrossRef
A Nomogram for Predicting Unplanned Intraoperative Hypothermia in Patients With Colorectal Cancer Undergoing Laparoscopic Colorectal Procedures
Lupei Yan, Jingxing Tan, Hao Chen, Han Xiao, Yi Zhang, Qin Yao, Yuerong Li
AORN Journal.2023;[Epub] CrossRef
A proposal for grading the risk of lymph node metastasis after endoscopic resection of T1 colorectal cancer
Zhenghua Piao, Rong Ge, Chunnian Wang
International Journal of Colorectal Disease.2023;[Epub] CrossRef
Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study
Yoshiki Kajiwara, Shiro Oka, Shinji Tanaka, Takahiro Nakamura, Shoichi Saito, Yosuke Fukunaga, Manabu Takamatsu, Hiroshi Kawachi, Kinichi Hotta, Hiroaki Ikematsu, Motohiro Kojima, Yutaka Saito, Masayoshi Yamada, Yukihide Kanemitsu, Shigeki Sekine, Shinji
Gastrointestinal Endoscopy.2023; 97(6): 1119. CrossRef
CT morphological features for predicting the risk of lymph node metastasis in T1 colorectal cancer
Suyun Li, Zhenhui Li, Li Wang, Mimi Wu, Xiaobo Chen, Chutong He, Yao Xu, Mengyi Dong, Yanting Liang, Xin Chen, Zaiyi Liu
European Radiology.2023; 33(10): 6861. CrossRef
Prediction model for lymph node metastasis in superficial colorectal cancer: a better choice than computed tomography
Chao-Tao Tang, Jun Li, Peng Wang, You-Xiang Chen, Chun-Yan Zeng
Surgical Endoscopy.2023; 37(10): 7444. CrossRef
Lymph Node Molecular Analysis with OSNA Enables the Identification of pT1 CRC Patients at Risk of Recurrence: A Multicentre Study
Karmele Saez de Gordoa, Maria Teresa Rodrigo-Calvo, Ivan Archilla, Sandra Lopez-Prades, Alba Diaz, Jordi Tarragona, Isidro Machado, Juan Ruiz Martín, Diana Zaffalon, Maria Daca-Alvarez, Maria Pellisé, Jordi Camps, Miriam Cuatrecasas
Cancers.2023; 15(22): 5481. CrossRef
Prediction of disease recurrence or residual disease after primary endoscopic resection of pT1 colorectal cancer—results from a large nationwide Danish study
Ilze Ose, Katarina Levic, Lau Caspar Thygesen, Orhan Bulut, Thue Bisgaard, Ismail Gögenur, Tine Plato Kuhlmann
International Journal of Colorectal Disease.2023;[Epub] CrossRef
Endoscopic resection alone as a potential treatment method for low-risk deep invasive T1 colorectal cancer
Yuta Kouyama, Shin-ei Kudo, Katsuro Ichimasa, Shingo Matsudaira, Yushi Ogawa, Kenichi Mochizuki, Yuki Takashina, Yuta Sato, Tatsuya Sakurai, Yasuharu Maeda, Hiroki Nakamura, Masashi Misawa, Yuichi Mori, Toyoki Kudo, Takemasa Hayashi, Kunihiko Wakamura, Te
iGIE.2023; 2(4): 503. CrossRef
A Retrospective Multicenter Study of Risk Factors, Stratification, and Prognosis of Lymph Node Metastasis in T1 and T2 Colorectal Cancer
Eui Myung Kim, Il Tae Son, Byung Chun Kim, Jun Ho Park, Byung Mo Kang, Jong Wan Kim
Journal of Clinical Medicine.2023; 12(24): 7744. CrossRef
Risk and Time Pattern of Recurrences After Local Endoscopic Resection of T1 Colorectal Cancer: A Meta-analysis
Hao Dang, Nik Dekkers, Saskia le Cessie, Jeanin E. van Hooft, Monique E. van Leerdam, Philip P. Oldenburg, Louis Flothuis, Jan W. Schoones, Alexandra M.J. Langers, James C.H. Hardwick, Jolein van der Kraan, Jurjen J. Boonstra
Clinical Gastroenterology and Hepatology.2022; 20(2): e298. CrossRef
Lymphatic Node Metastasis Risk Scoring System: A Novel Instrument for Predicting Lymph Node Metastasis After Thymic Epithelial Tumor Resection
Xinxin Cheng, Yaxin Lu, Sai Chen, Weilin Yang, Bo Xu, Jianyong Zou, Zhenguang Chen
Annals of Surgical Oncology.2022; 29(1): 598. CrossRef
Current problems and perspectives of pathological risk factors for lymph node metastasis in T1 colorectal cancer: Systematic review
Katsuro Ichimasa, Shin‐ei Kudo, Hideyuki Miyachi, Yuta Kouyama, Kenichi Mochizuki, Yuki Takashina, Yasuharu Maeda, Yuichi Mori, Toyoki Kudo, Yuki Miyata, Yoshika Akimoto, Yuki Kataoka, Takafumi Kubota, Tetsuo Nemoto, Fumio Ishida, Masashi Misawa
Digestive Endoscopy.2022; 34(5): 901. CrossRef
Tumor Location as a Prognostic Factor in T1 Colorectal Cancer
Katsuro Ichimasa, Shin-ei Kudo, Yuta Kouyama, Kenichi Mochizuki, Yuki Takashina, Masashi Misawa, Yuichi Mori, Takemasa Hayashi, Kunihiko Wakamura, Hideyuki Miyachi
Journal of the Anus, Rectum and Colon.2022; 6(1): 9. CrossRef
Identification of Predictive Factors for Lymph Node Metastasis in pT1 Stage Colorectal Cancer Patients: A Retrospective Analysis Based on the Population Database
Jiawei Song, Huanhuan Yin, Yong Zhu, Shengqi Fei
Pathology and Oncology Research.2022;[Epub] CrossRef
Establishment of a Dynamic Nomogram for Predicting the Risk of Lymph Node Metastasis in T1 Stage Colorectal Cancer
Zitao Liu, Chao Huang, Huakai Tian, Yu Liu, Yongshan Huang, Zhengming Zhu
Frontiers in Surgery.2022;[Epub] CrossRef
Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis
Liselotte W. Zwager, Barbara A.J. Bastiaansen, Nahid S.M. Montazeri, Roel Hompes, Valeria Barresi, Katsuro Ichimasa, Hiroshi Kawachi, Isidro Machado, Tadahiko Masaki, Weiqi Sheng, Shinji Tanaka, Kazutomo Togashi, Chihiro Yasue, Paul Fockens, Leon M.G. Moo
Gastroenterology.2022; 163(1): 174. CrossRef
Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer
Jeong-ki Kim, Ye-Young Rhee, Jeong Mo Bae, Jung Ho Kim, Seong-Joon Koh, Hyun Jung Lee, Jong Pil Im, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park, Ji Won Park, Gyeong Hoon Kang
BMC Cancer.2022;[Epub] CrossRef
Lymph node metastasis in T1 colorectal cancer with the only high-risk histology of submucosal invasion depth ≥ 1000 μm
Yusuke Yamaoka, Akio Shiomi, Hiroyasu Kagawa, Hitoshi Hino, Shoichi Manabe, Kai Chen, Kenji Nanishi, Akifumi Notsu
International Journal of Colorectal Disease.2022; 37(11): 2387. CrossRef
Subpopulation analysis of survival in high-risk T1 colorectal cancer: surgery versus endoscopic resection only
Ryun Kyong Ha, Boram Park, Kyung Su Han, Dae Kyung Sohn, Chang Won Hong, Byung Chang Kim, Bun Kim, Sung Chan Park, Hee Jin Chang, Jae Hwan Oh
Gastrointestinal Endoscopy.2022; 96(6): 1036. CrossRef
Preoperative prediction of lymph node status in patients with colorectal cancer. Developing a predictive model using machine learning
Morten Hartwig, Karoline Bendix Bräuner, Rasmus Vogelsang, Ismail Gögenur
International Journal of Colorectal Disease.2022; 37(12): 2517. CrossRef
Preoperative Predictors of Lymph Node Metastasis in Colon Cancer
Yansong Xu, Yi Chen, Chenyan Long, Huage Zhong, Fangfang Liang, Ling-xu Huang, Chuanyi Wei, Shaolong Lu, Weizhong Tang
Frontiers in Oncology.2021;[Epub] CrossRef
LASSO-Based Machine Learning Algorithm for Prediction of Lymph Node Metastasis in T1 Colorectal Cancer
Jeonghyun Kang, Yoon Jung Choi, Im-kyung Kim, Hye Sun Lee, Hogeun Kim, Seung Hyuk Baik, Nam Kyu Kim, Kang Young Lee
Cancer Research and Treatment.2021; 53(3): 773. CrossRef
Risk Stratification of T1 Colorectal Cancer Metastasis to Lymph Nodes: Current Status and Perspective
Katsuro Ichimasa, Shin-ei Kudo, Hideyuki Miyachi, Yuta Kouyama, Masashi Misawa, Yuichi Mori
Gut and Liver.2021; 15(6): 818. CrossRef
Supervised Learning Based Systemic Inflammatory Markers Enable Accurate Additional Surgery for pT1NxM0 Colorectal Cancer: A Comparative Analysis of Two Practical Prediction Models for Lymph Node Metastasis
Jinlian Jin, Haiyan Zhou, Shulin Sun, Zhe Tian, Haibing Ren, Jinwu Feng
Cancer Management and Research.2021; Volume 13: 8967. CrossRef
Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer
Kaibo Guo, Yuqian Feng, Li Yuan, Harpreet S. Wasan, Leitao Sun, Minhe Shen, Shanming Ruan
Cancer Medicine.2020; 9(14): 5095. CrossRef
Development and external validation of a predictive scoring system associated with metastasis of T1‐2 colorectal tumors to lymph nodes
Shaobo Mo, Zheng Zhou, Weixing Dai, Wenqiang Xiang, Lingyu Han, Long Zhang, Renjie Wang, Sanjun Cai, Qingguo Li, Guoxiang Cai
Clinical and Translational Medicine.2020; 10(1): 275. CrossRef
Inverse Association of Age with Risk of Lymph Node Metastasis in Superficial Colorectal Cancer: A Large Population-Based Study
Qing-Wei Zhang, Long-Ci Sun, Chao-Tao Tang, Qian Liang, Yang-Yang Zhou, Hui-Min Chen, Yun-Jie Gao, Zhi-Zheng Ge
The Oncologist.2020; 25(6): e920. CrossRef
T1 colorectal cancers: The impact of screening programs on a curable disease
Adriana Vaz Safatle-Ribeiro
Digestive and Liver Disease.2020; 52(8): 918. CrossRef
Risk factors and risk prediction models for colorectal cancer metastasis and recurrence: an umbrella review of systematic reviews and meta-analyses of observational studies
Wei Xu, Yazhou He, Yuming Wang, Xue Li, Jane Young, John P. A. Ioannidis, Malcolm G. Dunlop, Evropi Theodoratou
BMC Medicine.2020;[Epub] CrossRef

10,512 View
386 Download
44 Web of Science
42 Crossref

Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer: Sung Han Kim, Boram Park, Jae Young Joung, Jinsoo Chung, Ho Kyung Seo, Kang Hyun Lee, Weon Seo Park; Cancer Res Treat. 2019;51(3):910-918. Published online October 2, 2018; DOI: https://doi.org/10.4143/crt.2018.314

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to determine whether histologic inflammation (HI) in initial and repeat prostate biopsy specimens was significantly associated with the detection of prostate cancer.
Materials and Methods
Between 2005 and 2017, the clinicopathological records of patients with high prostatespecific antigen (PSA) levels who underwent initial and repeat prostate biopsies were retrospectively reviewed. The presence of HI and its degree in each biopsied specimen were interpreted by one uropathologist with 20 years of experience. The association between HI and cancer diagnosis was statistically assessed, with p < 0.05 considered significant, and the cancer and non-cancer groups were compared.
Results
Among the 522 patients with a median PSA levels of 6.5 ng/dL, including 258 (49.4%) whose cancer was diagnosed following repeat biopsy, the median degrees of HI in the initial and repeat biopsies were 25.0% and 41.7%, respectively. Furthermore, 211 (40.4%) and 247 (47.3%) patients had HI (> 0%) on biopsied specimens, respectively. Comparison of the cancer and noncancer groups revealed that a greater rate of HI specimens in the initial biopsy was associated with fewer prostate cancer diagnoses following repeat biopsy (p < 0.001). Other comparisons between the cancer and non-cancer groups showed that the cancer group had a significantly higher rate of hypertension, whereas those non-cancer group had a significantly higher rate of benign prostatic hyperplasia and prostatitis (p < 0.05).
Conclusion
A finding of a lesser degree of HI in the initial and a greater degree of HI in the repeat biopsied specimens was associated with the higher probability of cancer diagnosis in patients with high PSA levels.

Citations

Citations to this article as recorded by

Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
Benjamin A. Rybicki, Sudha M. Sadasivan, Yalei Chen, Oleksandr Kravtsov, Watchareepohn Palangmonthip, Kanika Arora, Nilesh S. Gupta, Sean Williamson, Kevin Bobbitt, Dhananjay A. Chitale, Deliang Tang, Andrew G. Rundle, Kenneth A. Iczkowski
Cancer Medicine.2021; 10(9): 3013. CrossRef

6,445 View
144 Download
1 Web of Science
1 Crossref

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: Eun-Gyeong Lee, Hyok Jo Kang, Myong Cheol Lim, Boyoung Park, Soo Jin Park, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Sang-Yoon Park, Boram Park, Jungnam Joo, Jai Hong Han, Sun-Young Kong, Eun Sook Lee; Cancer Res Treat. 2019;51(1):280-288. Published online May 4, 2018; DOI: https://doi.org/10.4143/crt.2018.079

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate decision patterns to reduce the risks of BRCArelated breast and gynecologic cancers in carriers of BRCA pathogenic variants. We found a change in risk-reducing (RR) management patterns after December 2012, when the National Health Insurance System (NHIS) of Korea began to pay for BRCA testing and riskreducing salpingo-oophorectomy (RRSO) in pathogenic-variant carriers.
Materials and Methods
The study group consisted of 992 patients, including 705 with breast cancer (BC), 23 with ovarian cancer (OC), 10 with both, and 254 relatives of high-risk patients who underwent BRCA testing at the National Cancer Center of Korea from January 2008 to December 2016.We analyzed patterns of and factors in RR management.
Results
Of the 992 patients, 220 (22.2%) were carriers of BRCA pathogenic variants. About 92.3% (203/220) had a family history of BC and/or OC,which significantly differed between BRCA1 and BRCA2 carriers (p < 0.001). All 41 male carriers chose surveillance. Of the 179 female carriers, 59 of the 83 carriers (71.1%) with BC and the 39 of 79 unaffected carriers (49.4%) underwent RR management. None of the carriers affected with OC underwent RR management. Of the management types, RRSO had the highest rate (42.5%) of patient choice. The rate of RR surgery was significantly higher after 2013 than before 2013 (46.3% [74/160] vs. 31.6% [6/19], p < 0.001).
Conclusion
RRSO was the preferred management for carriers of BRCA pathogenic variants. The most important factors in treatment choice were NHIS reimbursement and/or the severity of illness.

Citations

Citations to this article as recorded by

A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia
Filipa Alpeza, Christine Kim Yan Loo, Qingyuan Zhuang, Mikael Hartman, Serene Si Ning Goh, Jingmei Li
Cancers.2025; 17(2): 168. CrossRef
Risk-reducing decisions regarding germlineBRCApathogenic variant: focusing on the timing of genetic testing and RRSO
Akiko Abe, Hidetaka Nomura, Atsushi Fusegi, Mayu Yunokawa, Arisa Ueki, Eri Habano, Hiromi Arakawa, Keika Kaneko, Yuko Minoura, Hitoshi Inari, Takayuki Ueno, Hiroyuki Kanao
Journal of Medical Genetics.2024; 61(4): 392. CrossRef
BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study
Vera Loizzi, Michele Mongelli, Francesca Arezzo, Isabella Romagno, Gerardo Cazzato, Ondina Popescu, Francesco Legge, Paolo Trerotoli, Erica Silvestris, Anila Kardhashi, Gennaro Cormio
Gynecologic and Obstetric Investigation.2024; 89(2): 87. CrossRef
Implementation of BRCA Test among Young Breast Cancer Patients in South Korea: A Nationwide Cohort Study
Yung-Huyn Hwang, Tae-Kyung Yoo, Sae Byul Lee, Jisun Kim, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Il Yong Chung
Cancer Research and Treatment.2024; 56(3): 802. CrossRef
Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean BRCA1/2 Mutation Carriers
Dabin Kim, Jai Min Ryu, Sang-Ah Han, Zisun Kim, Sung-Won Kim
Current Oncology.2024; 31(11): 6767. CrossRef
Impact of graphical display on the intention to undergo risk-reducing salpingo-oophorectomy and mastectomy in individuals positive for BRCA pathogenic variant
Yoon-Jung Choi, Younju Park, Boyoung Park, Heejung Chae, So-Youn Jung, Kum Hei Ryu, Myong Cheol Lim, Soo Jin Park, Yoon Jung Chang, Sun-Young Kong
Scientific Reports.2024;[Epub] CrossRef
Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan
Hidetaka Nomura, Akiko Abe, Atsushi Fusegi, Teruyuki Yoshimitsu, Satoki Misaka, Atsushi Murakami, Tsuyoshi Matsumoto, Shiho Tsumura, Motoko Kanno, Yoichi Aoki, Sachiho Netsu, Makiko Omi, Terumi Tanigawa, Sanshiro Okamoto, Kohei Omatsu, Mayu Yunokawa, Hiro
Scientific Reports.2023;[Epub] CrossRef
Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study
Eun-Gyeong Lee, Jiwon Lim, Hyeong In Ha, Myong Cheol Lim, Yoon Jung Chang, Young-Joo Won, So-Youn Jung
Frontiers in Oncology.2023;[Epub] CrossRef
Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey
Yoon Jung Chang, Seungyeon Cho, Jungnam Joo, Kum Hei Ryu, Sangwon Lee, Juhee Cho, Myong Cheol Lim, So-Youn Jung, Jai Hong Han, Eun Sook Lee, Sun-Young Kong
Journal of Personalized Medicine.2022; 12(5): 818. CrossRef
Management of patients with BRCA mutation from the point of view of a breast surgeon
M.L. Riis
Annals of Medicine and Surgery.2021; 65: 102311. CrossRef
Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Young Min Hur, Jaehee Mun, Mi-Kyung Kim, Maria Lee, Yun Hwan Kim, Seung-Cheol Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Clinical significance of gene polymorphisms for hereditary predisposition to breast and ovarian cancer (review of literature)
D. I. Vodolazhsky, A. V. Mayakovskaya, A. V. Kubyshkin, K. A. Aliev, I. I. Fomochkina
Russian Clinical Laboratory Diagnostics.2021; 66(12): 760. CrossRef
Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation
Sung Mi Jung, Jai Min Ryu, Hyung Seok Park, Ji Soo Park, Eunyoung Kang, Seeyoun Lee, Han-Byoel Lee, Hyun Jo Youn, Tae-Kyung Yoo, Jisun Kim, Jeong Eon Lee, Sang Ah Han, Dongwon Kim, Sung-Won Kim
Journal of Breast Cancer.2020; 23(6): 647. CrossRef

11,144 View
231 Download
15 Web of Science
13 Crossref

Development and Evaluation of a Korean Version of a Thyroid-Specific Quality-of-Life Questionnaire Scale in Thyroid Cancer Patients: Chang Hwan Ryu, Boram Park, Junsun Ryu, Youn Mi Ryu, Seong Ae Jo, You Jin Lee, Eun-Kyung Lee, Yul Hwangbo, Jungnam Joo, Yuh-Seog Jung; Cancer Res Treat. 2018;50(2):405-415. Published online May 26, 2017; DOI: https://doi.org/10.4143/crt.2017.012

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to develop a Korean version of the self-reported thyroid-specific quality of life (QoL) questionnaire for thyroid cancer patients (KT-QoL), and to evaluate its reliability and validity.
Materials and Methods
Two hundred seventy-two patients who underwent thyroidectomy from January to December 2010 were recruited in this study. The original version of the thyroid QoL was translated into Korean and evaluated for its reliability and validity. Using the developed KT-QoL, the postoperative QoL was evaluated until postoperative 1 year.
Results
At the preoperative baseline, the item internal consistency (IIC) ranged from ‒0.19 to 0.76, with low IIC values for items 2, 17, and 27. Item discriminant validity ranged from 86% to 97%. These values were similar at the postoperative periods. The internal consistency reliability (Cronbach’s α) was high for all dimensions, ranging from 0.90 to 0.95. The test-retest reliability (intraclass correlation coefficient) was acceptable (0.74-0.82). The external validity examined by the correlation between the item 1j (voice changes) of KT-QoL and the voice handicap index-30 ranged from 0.51 to 0.75. Patients’ QoL scores decreased after surgery, which demonstrated the sensitivity of the questionnaire. The QoL scores in patients with lobectomy showed best QoL scores postoperatively and those with receiving radioactive iodine still showed decreased QoL scores along the postoperative periods.
Conclusion
These results demonstrate that KT-QoL is a valid instrument for evaluating QoL of Korean patients with thyroid cancer.

Citations

Citations to this article as recorded by

Laryngeal Electromyography as a Predictive Factor in the Evolution of Unilateral Recurrent Paralysis Post-Thyroidectomy
Shirley Tarabichi, Codrut Sarafoleanu
Journal of Clinical Medicine.2025; 14(4): 1047. CrossRef
Study Protocol of Expanded Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro-EXP)
Jae Hoon Moon, Eun Kyung Lee, Wonjae Cha, Young Jun Chai, Sun Wook Cho, June Young Choi, Sung Yong Choi, A Jung Chu, Eun-Jae Chung, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Kyungsik Kim, Min Joo Kim, Su-jin Kim, Woochul Kim, Yoo Hyung Kim, Chang Yoon Le
Endocrinology and Metabolism.2025; 40(2): 236. CrossRef
Health-Related Quality of Life in Patients with Low-Risk Differentiated Thyroid Cancer: A Systematic Review Examining the Extent of Thyroidectomy
Kathy Bach, Palvishey Ansari, Hamayail Ansari, Nicole M. Mott, Dawn M. Elfenbein, Hunter Underwood, Susan C. Pitt
Thyroid®.2024; 34(1): 14. CrossRef
Longitudinal Changes in Quality of Life Before and After Thyroidectomy in Patients With Differentiated Thyroid Cancer
Byung Hun Kim, Soo Rack Ryu, Jin Won Lee, Chang Myeon Song, Yong Bae Ji, Seok Hyun Cho, Seung Hwan Lee, Kyung Tae
The Journal of Clinical Endocrinology & Metabolism.2024; 109(6): 1505. CrossRef
Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi
Annals of Surgical Treatment and Research.2024; 106(1): 19. CrossRef
Five-Year Follow-Up of Health-Related Quality of Life in Differentiated Thyroid Cancer Patients Treated with Total Thyroidectomy and Radioiodine in Sweden: A Nationwide Prospective Cohort Study
Julia Winter, Erland Axelsson, Linda Björkhem-Bergman, Catharina Ihre Lundgren, Christel Hedman
Thyroid®.2024; 34(6): 713. CrossRef
Assessment of preoperative health-related quality of life in patients undergoing thyroidectomy based on patient-reported outcomes
Lei Liu, Yuqing Xiang, Lujing Xiong, Chao Li, Wei Dai, Jinchuan Hu, Chunyan Shui, Yuqiu Zhou, Xu Wang, Linjie Ma, Nan Xu, Bintao Hu, Yongcong Cai
Frontiers in Psychology.2024;[Epub] CrossRef
A Prospective Clinical Trial of Radiofrequency Ablation in Patients with Low-Risk Unifocal Papillary Thyroid Microcarcinoma Favoring Active Surveillance Over Surgery
Ji Ye Lee, Dong Gyu Na, Jung Suk Sim, Jin Yong Sung, Sun Wook Cho, Do Joon Park, Young Joo Park, Ji-hoon Kim
Thyroid®.2024; 34(9): 1126. CrossRef
Comparison of Patient-Reported Outcomes Between Active Surveillance and Immediate Lobectomy in Patients with Low-Risk Papillary Thyroid Microcarcinoma: Initial Findings from the KoMPASS Cohort
Min Joo Kim, Hojeong Won, Won Bae Kim, Eun Kyung Lee, Chang Yoon Lee, Sun Wook Cho, Han-Sang Baek, Yong Sang Lee, Yea Eun Kang, Sun Wook Kim, Ho-Cheol Kang, Jeongmin Lee, Mijin Kim, Min Ji Jeon, Jae Hoon Moon
Thyroid®.2024; 34(11): 1371. CrossRef
Optimizing surgical outcomes in papillary thyroid carcinoma with Hashimoto’s Thyroiditis: a retrospective comparative study of unilateral and total thyroidectomy
Xiaoyong Wen, Shiwei Zhou, Wu Li, Hui Li, Xiaohua Song, Yu Mao, Zeyu Li, Guangji Chen, Xiaowei Peng, Peng Wu
Scientific Reports.2024;[Epub] CrossRef
Quality of life in thyroid cancer
Torquil Watt, Thea Christoffersen, Mathilde Borring Brogaard, Jakob Bue Bjorner, Jens Bentzen, Christoffer Holst Hahn, Birte Nygaard, Ulla Feldt-Rasmussen
Best Practice & Research Clinical Endocrinology & Metabolism.2023; 37(1): 101732. CrossRef
Systematic review of health-related quality of life following thyroid cancer
Emma G Walshaw, Mike Smith, Dae Kim, Jonathan Wadsley, Anastasios Kanatas, Simon N. Rogers
Tumori Journal.2022; 108(4): 291. CrossRef
Factors affecting the health-promoting behavior of thyroid cancer survivors: comparison by stage of cancer survivorship
Kyung Ah Park, Sanghee Kim, Eui Geum Oh, Heejung Kim, Hang-Seok Chang, Soo Hyun Kim
Supportive Care in Cancer.2022; 30(4): 3429. CrossRef
Care and Management of Voice Change in Thyroid Surgery: Korean Society of Laryngology, Phoniatrics and Logopedics Clinical Practice Guideline
Chang Hwan Ryu, Seung Jin Lee, Jae-Gu Cho, Ik Joon Choi, Yoon Seok Choi, Yong Tae Hong, Soo Yeon Jung, Ji Won Kim, Doh Young Lee, Dong Kun Lee, GIljoon Lee, Sang Joon Lee, Young Chan Lee, Yong Sang Lee, Inn Chul Nam, Ki Nam Park, Young Min Park, Eui-Suk S
Clinical and Experimental Otorhinolaryngology.2022; 15(1): 24. CrossRef
Health-Related Quality of Life following Total Thyroidectomy and Lobectomy for Differentiated Thyroid Carcinoma: A Systematic Review
Vivianne Landry, Elizabeth Siciliani, Melissa Henry, Richard J. Payne
Current Oncology.2022; 29(7): 4386. CrossRef
Effect of radioiodine therapy under thyroid hormone withdrawal on health-related quality of life in patients with differentiated thyroid cancer
Hui Ming, Hui Yu, Yangbao Liu, Lihua Yang, Yuanhao Chen
Japanese Journal of Clinical Oncology.2022;[Epub] CrossRef
Thyroid disease‐specific quality of life questionnaires ‐ A systematic review
Verena Uslar, Caroline Becker, Dirk Weyhe, Navid Tabriz
Endocrinology, Diabetes & Metabolism.2022;[Epub] CrossRef
Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma
Jae Hoon Moon, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Jeong Hun Hah, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Ji Ye Lee, Kyu Eun Lee, You Jin Lee,
The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): 724. CrossRef
Singing voice range profile: New objective evaluation methods for voice change after thyroidectomy
Jungirl Seok, Youn Mi Ryu, Seong Ae Jo, Chang Yoon Lee, Yuh‐Seog Jung, Junsun Ryu, Chang Hwan Ryu
Clinical Otolaryngology.2021; 46(2): 332. CrossRef
A Propensity Score Matching Study Between Microwave Ablation and Radiofrequency Ablation in Terms of Safety and Efficacy for Benign Thyroid Nodules Treatment
Hao Jin, Jinrui Fan, Ligong Lu, Min Cui
Frontiers in Endocrinology.2021;[Epub] CrossRef
Adaptation transculturelle en Français du questionnaire évaluant la qualité de vie des patients opérés d’un cancer de la thyroïde : THYCA-QoL
Boris Scheller, Joseph Santini, Amélie Anota, Gilles Poissonnet, Y. Chateau, Renaud Schiappa, Danielle Benisvy, Olivier Dassonville, Alexandre Bozec, Emmanuel Chamorey
Bulletin du Cancer.2021; 108(7-8): 696. CrossRef
A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial
Eun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Park
Endocrinology and Metabolism.2020; 35(3): 571. CrossRef
Evaluation of Quality of Life in Patients with Differentiated Thyroid Cancer by Means of the Thyroid-Specific Patient-Reported Outcome Questionnaire: A 5-Year Longitudinal Study
Massimo Giusti, Stefano Gay, Lucia Conte, Francesca Cecoli, Lorenzo Mortara, Lara Vera, Eleonora Monti
European Thyroid Journal.2020; 9(5): 247. CrossRef
Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro)
Sung Hye Kong, Junsun Ryu, Min Joo Kim, Sun Wook Cho, Young Shin Song, Ka Hee Yi, Do Joon Park, Yul Hwangbo, You Jin Lee, Kyu Eun Lee, Su-jin Kim, Woo-Jin Jeong, Eun-Jae Chung, Jeong Hun Hah, June Young Choi, Chang Hwan Ryu, Yuh-Seog Jung, Jae Hoon Moon,
Thyroid.2019; 29(8): 1089. CrossRef
Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)
Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-jin Jung, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun Jae Jung, June Young Choi, Chang Hwan Ryu, You Jin Lee
Endocrinology and Metabolism.2018; 33(2): 278. CrossRef

17,628 View
335 Download
25 Web of Science
25 Crossref

Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study: Sang Myung Woo, Min Kyeong Kim, Jungnam Joo, Kyong-Ah Yoon, Boram Park, Sang-Jae Park, Sung-Sik Han, Ju Hee Lee, Eun Kyung Hong, Yun-Hee Kim, Hae Moon, Sun-Young Kong, Tae Hyun Kim, Woo Jin Lee; Cancer Res Treat. 2017;49(4):1022-1032. Published online January 19, 2017; DOI: https://doi.org/10.4143/crt.2016.495

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study assessed the feasibility and compliance of induction chemotherapy with gemcitabine and cisplatin followed by simultaneous integrated boost–intensity modulated radiotherapy (SIB-IMRT) with concurrent gemcitabine in patients with locally advanced unresectable pancreatic cancer.
Materials and Methods
In this trial, patients received induction chemotherapy consisting of gemcitabine (1,000 mg/m²) and cisplatin (25 mg/m2) on days 1, 8, and 15 of each treatment cycle. Patients were subsequently treated with gemcitabine (300 mg/m²/wk) during SIB-IMRT. The patients received total doses of 55 and 44 Gy in 22 fractions to planning target volume 1 and 2, respectively. As an ancillary study, digital polymerase chain reaction was performed to screen for the seven most common mutations in codons 12 and 13 of the KRAS oncogene of circulating cell free DNA (cfDNA).
Results
Forty-four patients were enrolled between 2012 and 2015. Of these, 33 (75%) completed the treatment. The most common toxicities during induction chemotherapy were grades 3 and 4 neutropenia (18.2%), grade 3 nausea (6.8%) and vomiting (6.8%). The most common toxicities during SIB-IMRT were grade 3 neutropenia (24.2%) and grade 3 anemia (12.1%). Ten patients (23%) underwent a curative resection after therapy. Median overall survival was significantly longer in patients who underwent curative resection (16.8 months vs. 11 months, p < 0.01). The median cfDNA concentration was significantly lower after treatment (108.5 ng/mL vs. 18.4 ng/mL, p < 0.001).
Conclusion
Induction chemotherapy with gemcitabine and cisplatin followed by concurrent SIB-IMRT was well tolerated and active.

Citations

Citations to this article as recorded by

Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma
Krishan R. Jethwa, Ed Kim, Jordan Berlin, Christopher J. Anker, Leila Tchelebi, Gerard Abood, Christopher L. Hallemeier, Salma Jabbour, Timothy Kennedy, Rachit Kumar, Percy Lee, Navesh Sharma, William Small, Vonetta Williams, Suzanne Russo
American Journal of Clinical Oncology.2024; 47(4): 185. CrossRef
Kinetics of plasma cell-free DNA as a prospective biomarker to predict the prognosis and radiotherapy effect of esophageal cancer
Y. Li, J. Wu, Y. Feng, D. Wang, H. Tao, J. Wen, F. Jiang, P. Qian, Y. Liu
Cancer/Radiothérapie.2024; 28(3): 242. CrossRef
Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?
Olivier Caliez, Daniel Pietrasz, Feryel Ksontini, Solène Doat, Jean-Marc Simon, Jean-Christophe Vaillant, Valerie Taly, Pierre Laurent-Puig, Jean-Baptiste Bachet
Digestive and Liver Disease.2022; 54(10): 1428. CrossRef
Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review
Marisol Huerta, Susana Roselló, Luis Sabater, Ana Ferrer, Noelia Tarazona, Desamparados Roda, Valentina Gambardella, Clara Alfaro-Cervelló, Marina Garcés-Albir, Andrés Cervantes, Maider Ibarrola-Villava
Cancers.2021; 13(5): 994. CrossRef
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Irina Palacín-Aliana, Noemí García-Romero, Adrià Asensi-Puig, Josefa Carrión-Navarro, Víctor González-Rumayor, Ángel Ayuso-Sacido
Biomedicines.2021; 9(8): 906. CrossRef
A review on the efficacy and safety of iodine-125 seed implantation in unresectable pancreatic cancers
Sheng-Nan Jia, Fu-Xing Wen, Ting-Ting Gong, Xin Li, Hui-Jie Wang, Ya-Min Sun, Ze-Cheng Yang
International Journal of Radiation Biology.2020; 96(3): 383. CrossRef
Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer
Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Eun Sang Oh, Sang Hee Youn, Hye Young Jang, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
Scientific Reports.2020;[Epub] CrossRef
Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment
Kyong-Ah Yoon, Sang Myung Woo, Yun-Hee Kim, Sun-Young Kong, Min Kyoung Lee, Sung-Sik Han, Tae Hyun Kim, Woo Jin Lee, Sang-Jae Park
Gut and Liver.2019; 13(6): 683. CrossRef
Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma
Sangjoon Park, Eun Jung Lee, Chai Hong Rim, Jinsil Seong
Yonsei Medical Journal.2018; 59(4): 470. CrossRef
Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer
Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Hyunjung Kim, Eun Sang Oh, Ju Hee Lee, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
Technology in Cancer Research & Treatment.2018;[Epub] CrossRef

10,316 View
255 Download
11 Web of Science
10 Crossref

Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418): Yeon-Joo Kim, Won Park, Boram Ha, Boram Park, Jungnam Joo, Tae Hyun Kim, In Hae Park, Keun Seok Lee, Eun Sook Lee, Kyung Hwan Shin, Haeyoung Kim, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2017;49(4):927-936. Published online December 26, 2016; DOI: https://doi.org/10.4143/crt.2016.508

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy.
Materials and Methods
We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010.
Results
We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081).
Conclusion
PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

Citations

Citations to this article as recorded by

Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
Munaser Alamoodi
European Journal of Breast Health.2024; 20(2): 81. CrossRef
Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer
Lin-Yu Xia, Wei-Yun Xu, Yan Zhao, Sudeep Gupta
PLOS ONE.2022; 17(6): e0270528. CrossRef
Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
Nalee Kim, Won Park, Won Kyung Cho, Hae Young Kim, Doo Ho Choi, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon
The Breast.2022; 66: 54. CrossRef
Post-mastectomy radiation therapy in breast cancer patients with 1–3 positive lymph nodes: No one size fits all
Majd Kayali, Joseph Abi Jaoude, Arafat Tfayli, Nagi El Saghir, Philip Poortmans, Youssef H. Zeidan
Critical Reviews in Oncology/Hematology.2020; 147: 102880. CrossRef
The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype
Jinli Wei, Yizhou Jiang, Zhimin Shao
The Breast.2020; 51: 40. CrossRef
The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
Lei Zhang, Ru Tang, Jia-Peng Deng, Wen-Wen Zhang, Huan-Xin Lin, San-Gang Wu, Zhen-Yu He
BMC Cancer.2020;[Epub] CrossRef
Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418)
Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Research and Treatment.2019; 51(3): 1041. CrossRef
Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
Jie Zhang, Xiao-Xiao Wang, Jun-Yu Lian, Chuan-Gui Song
Oncotarget.2019; 10(50): 5245. CrossRef
Local and regional recurrence following mastectomy in breast cancer patients with 1–3 positive nodes: implications for postmastectomy radiotherapy volume
Shin-Hyung Park, Jeeyeon Lee, Jeong Eun Lee, Min Kyu Kang, Mi Young Kim, Ho Yong Park, Jin Hyang Jung, Yee Soo Chae, Soo Jung Lee, Jae-Chul Kim
Radiation Oncology Journal.2018; 36(4): 285. CrossRef

11,450 View
346 Download
9 Web of Science
9 Crossref

Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer: Jungnam Joo, Kyong-Ah Yoon, Tomonori Hayashi, Sun-Young Kong, Hye-Jin Shin, Boram Park, Young Min Kim, Sang-Hyun Hwang, Jeongseon Kim, Aesun Shin, Joo-Young Kim; Cancer Res Treat. 2016;48(2):708-714. Published online June 22, 2015; DOI: https://doi.org/10.4143/crt.2015.098

Abstract PDF Supplementary Material PubReader ePub

Purpose
Defects in the DNA damage repair process can cause genomic instability and play an important role in cervical carcinogenesis. The purpose of this study was to analyze the association of 29 candidate single nucleotide polymorphisms (SNPs) in genes in the DNA repair pathway, TP53, and TP53BP1 with the risk of cervical cancer.
Materials and Methods
Twenty-nine SNPs in four genes in the DNA repair pathway (ERCC2, ERCC5, NBS1, and XRCC1), TP53, and TP53BP1 were genotyped for 478 cervical cancer patients and 922 healthy control subjects, and their effects on cervical carcinogenesis were analyzed.
Results
The most significant association was found for rs17655 in ERCC5, with an age-adjusted p-value < 0.0001, for which a strong additive effect of the risk allele C was observed (odds ratio, 2.01 for CC to GG). On the other hand, another significant polymorphism rs454421 in ERCC2 showed a dominant effect (odds ratio, 1.68 for GA+AA to GG) with an age-adjusted p-value of 0.0009. The association of these polymorphisms remained significant regardless of the age of onset. The significant result for rs17655 was also consistent for subgroups of patients defined by histology and human papillomavirus (HPV) types. However, for rs454421, the association was observed only in patients with squamous cell carcinoma and non-HPV 18 type.
Conclusion
The results of this study show a novel association of cervical cancer and the genes involved in the nucleotide excision pathway in the Korean population.

Citations

Citations to this article as recorded by

KIAA1549 promotes the development and chemoresistance of colorectal cancer by upregulating ERCC2
Feng Ye, Yuwen Xie, Mingdao Lin, Yang Liu, Yuan Fang, Keli Chen, Yaowei Zhang, Yi Ding
Molecular and Cellular Biochemistry.2024; 479(3): 629. CrossRef
Elucidation of Increased Cervical Cancer Risk Due to Polymorphisms in XRCC1 (R399Q and R194W), ERCC5 (D1104H), and NQO1 (P187S)
Agneesh Pratim Das, Sandeep Saini, Shrishty Tyagi, Nisha Chaudhary, Subhash Mohan Agarwal
Reproductive Sciences.2023; 30(4): 1118. CrossRef
Genetic polymorphisms in DNA repair genes and their association with risk of cervical cancer: A systematic review and meta‐analysis
Xueting Shao, Xiaole Yang, Ying Liu, Qingxia Song, Xin Pan, Wansu Chen, Wei Jiang, Dan Xu, Yuanyuan Song, Renshou Chen
Journal of Obstetrics and Gynaecology Research.2022; 48(9): 2405. CrossRef
Association of nonsynonymous SNPs of nucleotide excision repair genes ERCC4 rs1800067 (G/A) and ERCC5 rs17655 (G/C) as predisposing risk factors for gallbladder cancer
Kumari Anjali, Tarun Kumar, Puneet Kumar, Gopeshwar Narayan, Sunita Singh
Digestive and Liver Disease.2022; 54(11): 1533. CrossRef
Rare germline variants in DNA repair-related genes are accountable for papillary thyroid cancer susceptibility
Catia Mio, Antonella Verrienti, Valeria Pecce, Marialuisa Sponziello, Giuseppe Damante
Endocrine.2021; 73(3): 648. CrossRef
A meta-analysis of XRCC1 single nucleotide polymorphism and susceptibility to gynecological malignancies
Xue Qin Zhang, Li Li
Medicine.2021; 100(50): e28030. CrossRef
The association of integration patterns of human papilloma virus and single nucleotide polymorphisms on immune- or DNA repair-related genes in cervical cancer patients
Jungnam Joo, Yosuke Omae, Yuki Hitomi, Boram Park, Hye-Jin Shin, Kyong-Ah Yoon, Hiromi Sawai, Makoto Tsuiji, Tomonori Hayashi, Sun-Young Kong, Katsushi Tokunaga, Joo-Young Kim
Scientific Reports.2019;[Epub] CrossRef
The Pivotal Role of DNA Repair in Infection Mediated-Inflammation and Cancer
Ayse Z. Sahan, Tapas K. Hazra, Soumita Das
Frontiers in Microbiology.2018;[Epub] CrossRef
Somatic mutation load and spectra: A record of DNA damage and repair in healthy human cells
Natalie Saini, Dmitry A. Gordenin
Environmental and Molecular Mutagenesis.2018; 59(8): 672. CrossRef

12,423 View
92 Download
13 Web of Science
9 Crossref

Oncologists’ Experience with Patients with Second Primary Cancer and the Attitudes toward Second Primary Cancer Screening: A Nationwide Survey: Dong Wook Shin, Juhee Cho, Hyung Kook Yang, So Young Kim, Boram Park, BeLong Cho, Hyung Jin Kim, Young Jun Lee, Deog-Yeon Jo, Jong Hyock Park; Cancer Res Treat. 2015;47(4):600-606. Published online February 12, 2015; DOI: https://doi.org/10.4143/crt.2014.162

Abstract PDF PubReader ePub

Purpose
Screening for second primary cancer (SPC) is one of the key components to survivorship care. We aim to evaluate the oncologists’ experience with SPCs and assess the current practice, perceived barriers, and recommendations related to SPC screening. Materials and Methods A nationwide survey was conducted with a representative sample of 496 Korean oncologists. A questionnaire based on the findings from our previous qualitative study was administered. Results More than three-fourths of oncologists (76.3%), who participated in the study, had experience with SPC patients. Over half of them (51.9%) stated that it was an embarrassing experience. While the current management practice for SPC varies, most oncologists (80.2%) agreed on the necessity in proactively providing information on SPC screening. A short consultation time (52.3%), lack of guidelines and evidence on SPC screening (47.7%), and patients’ lack of knowledge about SPCs (45.1%) or SPC screening (41.4%) were most frequently reported as barriers to providing appropriate care for managing SPC. Oncologists recommended the development of specific screening programs or guidelines in accordance to the type of primary cancer (65.9%), the development of an internal system for SPC screening within the hospital (59.7%) or systematic connection with the national cancer screening program (44.3%), and education of oncologists (41.4%) as well as patients (48.9%) regarding SPC screening. Conclusion Many oncologists reported the occurrence of SPC as an embarrassing experience. Given the variations in current practice and the lack of consensus, further studies are warranted to develop the optimal clinical strategy to provide SPC screening for cancer survivors.

Citations

Citations to this article as recorded by

Cardiovascular risk and undertreatment of dyslipidemia in lung cancer survivors: A nationwide population-based study
In Young Cho, Kyungdo Han, Dong Wook Shin, Sang Hyun Park, Dong Woog Yoon, Sujeong Shin, Su-Min Jeong, Jong Ho Cho
Current Problems in Cancer.2021; 45(1): 100615. CrossRef
Developing an instrument to assess cancer patient preparedness for transition to survivorship care in Korea
Jung‐won Lim
Asian Social Work and Policy Review.2020; 14(3): 172. CrossRef
Second Primary Cancer after Treating Gastrointestinal Cancer
Jeong Youp Park
The Korean Journal of Gastroenterology.2019; 74(4): 193. CrossRef
A national survey of lung cancer specialists’ views on low-dose CT screening for lung cancer in Korea
Dong Wook Shin, Sohyun Chun, Young Il Kim, Seung Joon Kim, Jung Soo Kim, SeMin Chong, Young Sik Park, Sang-Yun Song, Jin Han Lee, Hee Kyung Ahn, Eun Young Kim, Sei Hoon Yang, Myoung Kyu Lee, Deog Gon Cho, Tae Won Jang, Ji Woong Son, Jeong-Seon Ryu, Moon-J
PLOS ONE.2018; 13(2): e0192626. CrossRef
The Dyadic Effects of Family Cohesion and Communication on Health-Related Quality of Life: The Moderating Role of Sex
Jung-won Lim, En-jung Shon
Cancer Nursing.2018; 41(2): 156. CrossRef
Physicians’ attitudes towards the media and peer-review selection of the ‘best cancer doctor’: comparison of two different selection methods
Dong Wook Shin, Juhee Cho, Hyung Kook Yang, So Young Kim, Soohyeon Lee, Eun Joo Nam, Joo Seop Chung, Jeong-Soo Im, Keeho Park, Jong Hyock Park
BMJ Open.2018; 8(5): e019067. CrossRef

10,528 View
91 Download
5 Web of Science
6 Crossref

First
Prev
Page of 1
Next
Last

Search